CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the
The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA CAMBRIDGE, Mass., July 14, 2026
New Chief Financial Officer and Chief Legal Officer and Head of Corporate Affairs follow recent appointment of Kevin Lind as Chief Executive Officer, in a planned succession strategy preparing Apnimed for its next stage of growth Michael Kelly brings more than 25 years of healthcare finance
CAMBRIDGE, Mass., June 10, 2026 – Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that six abstracts have been
Mr. Lind succeeds Company founder Lawrence G. Miller, MD, who is transitioning to Vice Chair of the Board Mr. Lind brings significant prior CEO, commercial, financial and capital markets experience, including leading Longboard Pharmaceuticals to an acquisition by H.
Companion mechanistic review article published concurrently in the American Journal of Respiratory Cell and Molecular Biology in first-of-its-kind dual publications Publications reinforce AD109’s potential, if approved, as a first-in-class oral pill designed to improve oxygenation during
CAMBRIDGE, Mass. May 11, 2026 – Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced multiple presentations,
Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA) On track to submit New Drug Application (NDA) for AD109 later this quarter CAMBRIDGE, Mass., April 6th, 2026 – Apnimed, Inc., a pharmaceutical
Transaction strengthens Apnimed’s balance sheet as the Company separately prepares to submit its NDA for AD109 in Obstructive Sleep Apnea, expected in the second quarter of 2026 Apnimed retains exclusive rights to AD109 CAMBRIDGE, Mass., March 24, 2026 – Apnimed, Inc., a pharmaceutical company
